JP2020515518A5 - - Google Patents

Download PDF

Info

Publication number
JP2020515518A5
JP2020515518A5 JP2019538382A JP2019538382A JP2020515518A5 JP 2020515518 A5 JP2020515518 A5 JP 2020515518A5 JP 2019538382 A JP2019538382 A JP 2019538382A JP 2019538382 A JP2019538382 A JP 2019538382A JP 2020515518 A5 JP2020515518 A5 JP 2020515518A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
polypeptide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019538382A
Other languages
English (en)
Japanese (ja)
Other versions
JP7219220B2 (ja
JP2020515518A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/051083 external-priority patent/WO2018134235A1/en
Publication of JP2020515518A publication Critical patent/JP2020515518A/ja
Publication of JP2020515518A5 publication Critical patent/JP2020515518A5/ja
Priority to JP2022196232A priority Critical patent/JP7628996B2/ja
Application granted granted Critical
Publication of JP7219220B2 publication Critical patent/JP7219220B2/ja
Priority to JP2024204085A priority patent/JP2025026992A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019538382A 2017-01-17 2018-01-17 改善された血清アルブミン結合剤 Active JP7219220B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022196232A JP7628996B2 (ja) 2017-01-17 2022-12-08 改善された血清アルブミン結合剤
JP2024204085A JP2025026992A (ja) 2017-01-17 2024-11-22 改善された血清アルブミン結合剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762446988P 2017-01-17 2017-01-17
US62/446,988 2017-01-17
PCT/EP2018/051083 WO2018134235A1 (en) 2017-01-17 2018-01-17 Improved serum albumin binders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022196232A Division JP7628996B2 (ja) 2017-01-17 2022-12-08 改善された血清アルブミン結合剤

Publications (3)

Publication Number Publication Date
JP2020515518A JP2020515518A (ja) 2020-05-28
JP2020515518A5 true JP2020515518A5 (cg-RX-API-DMAC7.html) 2021-01-07
JP7219220B2 JP7219220B2 (ja) 2023-02-07

Family

ID=61521465

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019538382A Active JP7219220B2 (ja) 2017-01-17 2018-01-17 改善された血清アルブミン結合剤
JP2022196232A Active JP7628996B2 (ja) 2017-01-17 2022-12-08 改善された血清アルブミン結合剤
JP2024204085A Pending JP2025026992A (ja) 2017-01-17 2024-11-22 改善された血清アルブミン結合剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022196232A Active JP7628996B2 (ja) 2017-01-17 2022-12-08 改善された血清アルブミン結合剤
JP2024204085A Pending JP2025026992A (ja) 2017-01-17 2024-11-22 改善された血清アルブミン結合剤

Country Status (21)

Country Link
US (2) US11414481B2 (cg-RX-API-DMAC7.html)
EP (3) EP4442709A3 (cg-RX-API-DMAC7.html)
JP (3) JP7219220B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240013861A (cg-RX-API-DMAC7.html)
CN (2) CN117285623A (cg-RX-API-DMAC7.html)
AU (2) AU2018209151B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019014599A2 (cg-RX-API-DMAC7.html)
CA (1) CA3050575A1 (cg-RX-API-DMAC7.html)
DK (1) DK3571225T3 (cg-RX-API-DMAC7.html)
ES (1) ES2991459T3 (cg-RX-API-DMAC7.html)
FI (1) FI3571225T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241469T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068790T2 (cg-RX-API-DMAC7.html)
IL (2) IL267894B2 (cg-RX-API-DMAC7.html)
LT (1) LT3571225T (cg-RX-API-DMAC7.html)
MX (2) MX2019008496A (cg-RX-API-DMAC7.html)
PT (1) PT3571225T (cg-RX-API-DMAC7.html)
RS (1) RS66117B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201906264YA (cg-RX-API-DMAC7.html)
SI (1) SI3571225T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018134235A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG194982A1 (en) 2011-06-23 2013-12-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
DK3571225T3 (da) * 2017-01-17 2024-11-04 Ablynx Nv Forbedrede serumalbuminbindere
WO2018134234A1 (en) * 2017-01-17 2018-07-26 Ablynx Nv Improved serum albumin binders
PH12022551214A1 (en) 2019-12-06 2023-10-09 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnf# and il-23
WO2021110817A1 (en) 2019-12-06 2021-06-10 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
WO2021116182A1 (en) 2019-12-09 2021-06-17 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
MX2022012278A (es) 2020-03-30 2022-10-27 Ablynx Nv Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes.
MX2023003522A (es) 2020-09-25 2023-04-19 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
KR20230123495A (ko) 2020-12-18 2023-08-23 아블린쓰 엔.브이. 글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드
AU2021402090A1 (en) 2020-12-18 2023-08-03 Ablynx Nv T cell recruiting polypeptides based on tcr alpha/beta reactivity
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
WO2023111266A1 (en) 2021-12-17 2023-06-22 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
IL317588A (en) 2022-06-14 2025-02-01 Ablynx Nv Single immunoglobulin variable sites targeting the T cell receptor
KR20250042176A (ko) 2022-07-27 2025-03-26 아블린쓰 신생아 fc 수용체의 특정 에피토프에 결합하는 폴리펩타이드
WO2024084203A1 (en) 2022-10-18 2024-04-25 Isogenica Limited Single domain antibodies binding to albumin
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
KR20250133750A (ko) 2023-01-09 2025-09-08 오디세이 테라퓨틱스, 인코포레이티드 항-tnfr2 항원-결합 단백질 및 그의 용도
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
AU2024234615A1 (en) 2023-03-14 2025-08-21 Odyssey Therapeutics, Inc. Anti-cd25 antigen-binding proteins and uses thereof
AU2024273077A1 (en) 2023-05-17 2025-11-13 Odyssey Therapeutics, Inc. Modified single-domain antibodies
KR102822958B1 (ko) * 2023-05-23 2025-06-20 대한민국(해양경찰청 해양경찰연구센터장) 고래 불법포획 감식용 신속진단키트
WO2024261235A1 (en) 2023-06-22 2024-12-26 Ablynx Nv Chimeric proteins for modulating cytokine receptor activity
TW202515917A (zh) 2023-06-29 2025-04-16 美商奧迪希治療公司 抗trailr2抗原結合蛋白及其用途
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
WO2025051767A1 (en) 2023-09-04 2025-03-13 Sanofi Polypeptides for use in the treatment of glypican-3-expressing tumours
TW202532432A (zh) 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑
WO2025080751A2 (en) 2023-10-13 2025-04-17 Odyssey Therapeutics, Inc. Anti-cdh17 antigen-binding proteins and uses thereof
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
US20250296991A1 (en) 2023-12-01 2025-09-25 Ablynx N.V. Precision activated polypeptides
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025217579A1 (en) * 2024-04-12 2025-10-16 Paragon Therapeutics, Inc. Anti-hsa vhh antibodies and compositions thereof
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use
WO2025255558A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof
WO2025255435A2 (en) 2024-06-07 2025-12-11 Odyssey Therapeutics, Inc. Antigen-binding proteins against serum albumin and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CN1203178C (zh) 1997-10-27 2005-05-25 尤尼利弗公司 多价抗原结合蛋白
US6742038B2 (en) 2000-04-07 2004-05-25 Danger, Inc. System and method of linking user identification to a subscriber identification module
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2512545C (en) 2003-01-10 2015-06-30 Karen Silence Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
MX2007006593A (es) 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
RU2433139C2 (ru) 2005-05-20 2011-11-10 Аблинкс Н.В. Nanobodies tm для лечения заболеваний, опосредованных агрегацией
EP1957536A2 (en) 2005-12-01 2008-08-20 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
WO2007063311A2 (en) 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
WO2007085814A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン.ヴェー. Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
JP2010502208A (ja) 2006-09-08 2010-01-28 アブリンクス エン.ヴェー. 半減期の長い血清アルブミン結合タンパク質
EP2152747B1 (en) 2007-05-24 2018-01-03 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
MX2010005783A (es) 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
BRPI0911984A2 (pt) 2008-05-16 2016-09-20 Ablynx Nv sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos
CA2737241C (en) * 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
JP2012532620A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド 改良型抗血清アルブミン結合単一可変ドメイン
CN102666586A (zh) 2009-09-30 2012-09-12 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
SG188204A1 (en) 2010-08-20 2013-04-30 Glaxo Group Ltd Improved anti-serum albumin binding variants
US11644471B2 (en) * 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP3020728A1 (en) * 2011-06-23 2016-05-18 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
US20150344568A1 (en) * 2011-06-23 2015-12-03 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG194982A1 (en) 2011-06-23 2013-12-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CN106046168A (zh) 2011-06-23 2016-10-26 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
WO2012174741A1 (en) 2011-06-24 2012-12-27 Google Inc. Determining cross-language query suggestion based on query translations
UA118833C2 (uk) 2011-08-17 2019-03-25 Ґлаксо Ґруп Лімітед Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
WO2014037419A1 (en) 2012-09-04 2014-03-13 Vib Vzw Immunoglobulin single variable domains directed against cd74 and uses derived thereof
US20140186365A1 (en) * 2013-01-03 2014-07-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
RS63085B1 (sr) 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
EP3247407A4 (en) 2015-01-21 2018-08-22 Inhibrx LP Non-immunogenic single domain antibodies
ES2754427T3 (es) 2015-05-13 2020-04-17 Ablynx Nv Polipéptidos de reclutamiento de células T basados en la reactividad de TCR alfa/beta
PL3374392T3 (pl) * 2015-11-13 2022-03-28 Ablynx Nv Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy
SG11201803976VA (en) 2015-11-27 2018-06-28 Ablynx Nv Polypeptides inhibiting cd40l
WO2018104444A1 (en) 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
WO2018134234A1 (en) * 2017-01-17 2018-07-26 Ablynx Nv Improved serum albumin binders
DK3571225T3 (da) * 2017-01-17 2024-11-04 Ablynx Nv Forbedrede serumalbuminbindere
TW202532432A (zh) * 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑

Similar Documents

Publication Publication Date Title
JP2020515518A5 (cg-RX-API-DMAC7.html)
JP2020506898A5 (cg-RX-API-DMAC7.html)
JP7453206B2 (ja) 改良された血清アルブミン結合剤
RU2022101604A (ru) Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
AU2016351710B2 (en) Improved serum albumin-binding immunoglobulin variable domains
IL305912A (en) Improved serum albumin binders
JP2018537421A5 (cg-RX-API-DMAC7.html)
IL312292A (en) Improved serum albumin binders
JPWO2020069028A5 (cg-RX-API-DMAC7.html)
JP2020500510A5 (cg-RX-API-DMAC7.html)
JP2017519503A5 (cg-RX-API-DMAC7.html)
JPWO2022111425A5 (cg-RX-API-DMAC7.html)
RU2023110757A (ru) Усовершенствованные агенты, связывающие сывороточный альбумин
RU2023102139A (ru) Усовершенствованные связывающиеся с сывороточным альбумином вещества
RU2019118441A (ru) Рекрутирующие т-клетки полипептиды, способные связывать cd123 и tcr альфа/бета